Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial

Lancet
C CourtneyAD2000 Collaborative Group

Abstract

Cholinesterase inhibitors produce small improvements in cognitive and global assessments in Alzheimer's disease. We aimed to determine whether donepezil produces worthwhile improvements in disability, dependency, behavioural and psychological symptoms, carers' psychological wellbeing, or delay in institutionalisation. If so, which patients benefit, from what dose, and for how long? 565 community-resident patients with mild to moderate Alzheimer's disease entered a 12-week run-in period in which they were randomly allocated donepezil (5 mg/day) or placebo. 486 who completed this period were rerandomised to either donepezil (5 or 10 mg/day) or placebo, with double-blind treatment continuing as long as judged appropriate. Primary endpoints were entry to institutional care and progression of disability, defined by loss of either two of four basic, or six of 11 instrumental, activities on the Bristol activities of daily living scale (BADLS). Outcome assessments were sought for all patients and analysed by logrank and multilevel models. Cognition averaged 0.8 MMSE (mini-mental state examination) points better (95% CI 0.5-1.2; p<0.0001) and functionality 1.0 BADLS points better (0.5-1.6; p<0.0001) with donepezil over the first 2 years...Continue Reading

Citations

Nov 9, 2005·Archives of General Psychiatry·Roger N Rosenberg
Nov 17, 2007·Aging Clinical and Experimental Research·Giovanni B FrisoniOrazio Zanetti
Mar 22, 2005·Psychopharmacology·Oliver FreudenreichDonald C Goff
May 25, 2005·European Journal of Clinical Pharmacology·Roberto RaschettiNicola Vanacore
Jan 30, 2008·European Journal of Clinical Pharmacology·Silvio Garattini, Vittorio Bertele'
Apr 4, 2007·European Archives of Psychiatry and Clinical Neuroscience·Stefan J TeipelMichael Happich
Jun 28, 2011·Journal of Neurology·Daniela Galimberti, Elio Scarpini
Dec 22, 2010·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Martina Zimmermann
Aug 25, 2006·Current Neurology and Neuroscience Reports·David S Knopman
Oct 24, 2013·Aging Clinical and Experimental Research·Carlotta FranchiAlessandro Nobili
Apr 20, 2005·Neurobiology of Disease·Martina ZimmermannMonica Di Luca
Jul 16, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Abraham Fisher
Jul 16, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Neil UptonDavid J Virley
Mar 30, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Christa M StudzinskiNorton W Milgram
Mar 11, 2010·International Psychogeriatrics·Edward Alan MillerRobert A Rosenheck
Jul 31, 2010·International Psychogeriatrics·Samantha A Hollingworth, Gerard J Byrne
Dec 23, 2011·International Psychogeriatrics·Lon S Schneider
Nov 1, 2005·Epidemiologia e psichiatria sociale·John R Geddes
Aug 26, 2006·Nature Clinical Practice. Neurology·Thomas E Finucane, John R Gilstad
Sep 3, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Ariel RokemMichael A Silver
Mar 10, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Brian M BennettGregory R J Thatcher
Jul 27, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Laura KentonDonald P Cain
Oct 29, 2004·The New England Journal of Medicine·Jack de la TorreGeorge Perry
Oct 29, 2010·The New England Journal of Medicine·Lisa LavelleDiarmuid O'Shea
Jul 19, 2013·The New England Journal of Medicine·Nicholas Kozauer, Russell Katz
Dec 14, 2004·The New England Journal of Medicine·Daniel Z Press
Apr 15, 2005·The New England Journal of Medicine·Deborah Blacker
Mar 9, 2012·The New England Journal of Medicine·Robert HowardPatrick Phillips
Feb 16, 2010·Aging & Mental Health·Claudia CooperGill Livingston
Apr 27, 2010·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Yukiko YoshidaTsunehiko Ikeda
Dec 19, 2006·Evidence-based Complementary and Alternative Medicine : ECAM·Leopoldo Luiz Dos Santos-NetoGustavo Almeida de Souza
May 25, 2006·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Sophie Gillette-GuyonnetBruno Vellas
Feb 5, 2008·Schizophrenia Bulletin·T Scott Stroup, John R Geddes

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Alzheimer's Disease: APOE

Apolipoprotein E (APOE) polymorphic alleles are major genetic risk factors for Alzheimer's disease. Discover the latest research on APOE and other genetic determinants of Alzheimer's disease here.